StreetInsider.com (subscription) | Pre-Open Stock Movers 10/10: (ACUR) (CHTP) (NFLX) Higher; (CTXS) (RT ... StreetInsider.com (subscription) This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving ... |
